Clinical Trial Update: Brentuximab Vedotin, Bendamustine, and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma [Phase 2]

View source ↗

Summary

The Phase 2 trial of Brentuximab Vedotin, Bendamustine, and Rituximab for relapsed or refractory B-cell non-Hodgkin lymphoma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma
• Grey Zone Lymphoma
• High-grade B-cell Lymphoma
• Marginal Zone Lymphoma
• Mediastinal Large B-cell Lymphoma
• Small Lymphocytic Lymphoma

Drugs mentioned

• Bendamustine (Bendamustine)
• Brentuximab vedotin (Brentuximab vedotin)
• Rituxan (rituximab)

Snippet

Sponsor: University of Arizona | Conditions: Diffuse Large B Cell Lymphoma, Mediastinal Large B-cell Lymphoma | Phase 2 | Status: WITHDRAWN